Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0M0KB
|
|||
| Former ID |
DIB016445
|
|||
| Drug Name |
MK-6592
|
|||
| Synonyms |
VX-667
Click to Show/Hide
|
|||
| Indication | Solid tumour/cancer [ICD-11: 2A00-2F9Z; ICD-10: C76-C80; ICD-9: 140-229] | Discontinued in Phase 1 | [1] | |
| Company |
Vertex Pharmaceuticals Inc
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C25H26ClF2N7O2
|
|||
| Canonical SMILES |
CC1=CC(=NN1)NC2=CC(=NC(=N2)OC3CCN(C3)C(=O)C4=C(C=CC(=C4)Cl)F)N5CC(C5)(C6CC6)F
|
|||
| InChI |
1S/C25H26ClF2N7O2/c1-14-8-21(33-32-14)29-20-10-22(35-12-25(28,13-35)15-2-3-15)31-24(30-20)37-17-6-7-34(11-17)23(36)18-9-16(26)4-5-19(18)27/h4-5,8-10,15,17H,2-3,6-7,11-13H2,1H3,(H2,29,30,31,32,33)/t17-/m0/s1
|
|||
| InChIKey |
SLUHYAXFRJQTGB-KRWDZBQOSA-N
|
|||
| PubChem Compound ID | ||||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Aurora kinase C (AURKC) | Target Info | Inhibitor | [2] |
| KEGG Pathway | Oocyte meiosis | |||
| Reactome | APC/C:Cdh1 mediated degradation of Cdc20 and other APC/C:Cdh1 targeted proteins in late mitosis/early G1 | |||
| Separation of Sister Chromatids | ||||
| Resolution of Sister Chromatid Cohesion | ||||
| RHO GTPases Activate Formins | ||||
| WikiPathways | EGF/EGFR Signaling Pathway | |||
| JAK/STAT | ||||
| Gastric Cancer Network 1 | ||||
| Integrated Breast Cancer Pathway | ||||
| APC/C-mediated degradation of cell cycle proteins | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800024789) | |||
| REF 2 | Clinical experience with aurora kinase inhibitors: a review. Oncologist. 2009 Aug;14(8):780-93. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.